Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Blood (2024) 143 (6): 496–506.

https://doi.org/10.1182/blood.2023021243

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Amneet K Bajwa, Qiuhong Zhao, Marcus Johannes Geer, Agrima Mian, Chenyu Lin, David Frame, James Westholder, Justin Tossey, Monalisa Ghosh, Ahmed Galal, Nausheen Ahmed, Joseph E. Maakaron, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo F. Caimi, Timothy Voorhees

Blood (2023) 142 (Supplement 1): 4502.

https://doi.org/10.1182/blood-2023-179620

Published: 2023

Journal Articles

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Blood (2023) 142 (Supplement 1): 380.

https://doi.org/10.1182/blood-2023-189505

Published: 2023

Journal Articles

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Blood (2023) 142 (Supplement 1): 2407.

https://doi.org/10.1182/blood-2023-183041

Published: 2023

Journal Articles

A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma

Asaad Trabolsi, Narendranath Epperla, Kaitlin Annunzio, Dan Morgenstern Kaplan, Peter Doukas, Frederique St-Pierre, Brittany McCall, Lindsey Fitzgerald, Sunwoo Han, Isildinha M. Reis, Jennifer Rose Chapman-Fredricks, Khaled Alhamad, Thomas Ollila, Reem Karmali, Izidore S. Lossos, Juan Pablo Alderuccio

Blood (2023) 142 (Supplement 1): 3770.

https://doi.org/10.1182/blood-2023-173905

Published: 2023

Journal Articles

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Yazeed Sawalha, Rina Li Welkie, Anna Krivenko, Brian Hess, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C Reneau, Narendranath Epperla, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks

Blood (2023) 142 (Supplement 1): 6226.

https://doi.org/10.1182/blood-2023-182941

Published: 2023

Journal Articles

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Blood (2023) 142 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2023-181056

Published: 2023

Journal Articles

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

Alessandra Tedeschi, Chan Yoon Cheah, Stephen S. Opat, Emma Verner, Laura Magnano, Narendranath Epperla, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Mary Ann Anderson

Blood (2023) 142 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2023-178841

Published: 2023

Journal Articles

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Blood (2023) 142 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2023-183011

Published: 2023

Journal Articles

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Narendranath Epperla, Natalie S. Grover, Kaitlin Annunzio, Marcus P Watkins, Pallawi Torka, Reem Karmali, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey P. Shouse, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 266.

https://doi.org/10.1182/blood-2023-185152

Published: 2023

Journal Articles

Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States

Narendranath Epperla, Loretta J. Nastoupil, Kristin M. Zimmerman Savill, Bruce Feinberg, John Galvin, Prathamesh Pathak, Sarah Gordon, Theresa Amoloja, Mae Llorente, Kimberly Saverno

Blood (2023) 142 (Supplement 1): 2415.

https://doi.org/10.1182/blood-2023-173456

Published: 2023

Journal Articles

Survival of Patients with Transformed Marginal Zone Lymphoma in the United States: A Population-Based Cohort Study

John L Vaughn, Narendranath Epperla

Blood (2023) 142 (Supplement 1): 5141.

https://doi.org/10.1182/blood-2023-190955

Published: 2023

Journal Articles

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Narendranath Epperla, Kaitlin Annunzio, Geoffrey P. Shouse, Natalie S. Grover, Pallawi Torka, Marcus P Watkins, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2023-185205

Published: 2023

Journal Articles

Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting

Kimberly Saverno, Kristin M. Zimmerman Savill, Bruce Feinberg, John Galvin, Prathamesh Pathak, Sarah Gordon, Theresa Amoloja, Mae Llorente, Narendranath Epperla, Loretta J. Nastoupil

Blood (2023) 142 (Supplement 1): 265.

https://doi.org/10.1182/blood-2023-173143

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Blood (2023) 142 (Supplement 1): 900.

https://doi.org/10.1182/blood-2023-182385

Published: 2023

Journal Articles

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Allison M Lehanka, Ann Kebede, Neda Amirmokhtari, Joseph R Stanek, Narendranath Epperla, Beth Christian, Robert Baiocchi, Timothy Voorhees, Kami J. Maddocks, Yazeed Sawalha, John C Reneau, Jonathan E. Brammer, Audrey M. Sigmund, Faye Willen, Nick Yeager, Anthony N. Audino, David A. Bond

Blood (2023) 142 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2023-187194

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

Cardiovascular Toxicities Associated with Bispecific T-Cell Engagers

Ahmed Sayed, Malak Munir, Sanam Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sarah Khan, Sneha Sharma, Alexa Mera, Narendranath Epperla, Daniel Addison

Blood (2023) 142 (Supplement 1): 2882.

https://doi.org/10.1182/blood-2023-189603

Published: 2023

Journal Articles

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Blood (2023) 142 (Supplement 1): 382.

https://doi.org/10.1182/blood-2023-182389

Published: 2023

Journal Articles

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Blood (2023) 142 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2023-185182

Published: 2023

NARROW

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States

Survival of Patients with Transformed Marginal Zone Lymphoma in the United States: A Population-Based Cohort Study

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Cardiovascular Toxicities Associated with Bispecific T-Cell Engagers

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only